{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T17:12:50Z","timestamp":1792257170367,"version":"4.4.0"},"reference-count":140,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>Reduced exposure to echinocandins has been reported in specific patient populations, such as critically ill patients; however, fixed dosing strategies are still used. The present review examines the accumulated evidence supporting echinocandin therapeutic drug monitoring (TDM) and summarizes available assays and sampling strategies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A literature search was conducted using PubMed in December 2020, with search terms such as echinocandins, anidulafungin, caspofungin, micafungin, or rezafungin with pharmacology, pharmacokinetics (PKs), pharmacodynamics (PDs), drug\u2013drug interactions, TDM, resistance, drug susceptibility testing, toxicity, adverse drug reactions, bioanalysis, chromatography, and mass spectrometry. Data on PD\/PD (PK\/PD) outcome markers, drug resistance, PK variability, drug\u2013drug interactions, assays, and TDM sampling strategies were summarized.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Echinocandins demonstrate drug exposure\u2013efficacy relationships, and maximum concentration\/minimal inhibitory concentration ratio (C<jats:sub>max<\/jats:sub>\/MIC) and area under the concentration\u2013time curve\/MIC ratio (AUC\/MIC) are proposed PK\/PD markers for clinical response. The relationship between drug exposure and toxicity remains poorly clarified. TDM could be valuable in patients at risk of low drug exposure, such as those with critical illness and\/or obesity. TDM of echinocandins may also be useful in patients with moderate liver impairment, drug\u2013drug interactions, hypoalbuminemia, and those undergoing extracorporeal membrane oxygenation, as these conditions are associated with altered exposure to caspofungin and\/or micafungin. Assays are available to measure anidulafungin, micafungin, and caspofungin concentrations. A limited-sampling strategy for anidulafungin has been reported.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Echinocandin TDM should be considered in patients at known risk of suboptimal drug exposure. However, for implementing TDM, clinical validation of PK\/PD targets is needed.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000931","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T23:20:23Z","timestamp":1634685623000},"page":"198-214","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":38,"title":["Therapeutic Drug Monitoring of the Echinocandin Antifungal Agents: Is There a Role in Clinical Practice? A Position Statement of the Anti-Infective Drugs Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology"],"prefix":"10.1097","volume":"44","author":[{"given":"Hannah Yejin","family":"Kim","sequence":"first","affiliation":[{"name":"Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia;"},{"name":"Westmead Hospital, Westmead, NSW, Australia;"},{"name":"Marie Bashir Institute for Infectious Diseases and Biosecurity, The University of Sydney, Camperdown, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Baldelli","sequence":"additional","affiliation":[{"name":"Unit of Clinical Pharmacology, Fatebenefratelli Sacco University Hospital, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Grete","family":"M\u00e4rtson","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Stocker","sequence":"additional","affiliation":[{"name":"Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia;"},{"name":"St Vincent's Clinical School, University of New South Wales, Kensington, NSW Australia; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6703-0288","authenticated-orcid":false,"given":"Jan-Willem","family":"Alffenaar","sequence":"additional","affiliation":[{"name":"Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia;"},{"name":"Westmead Hospital, Westmead, NSW, Australia;"},{"name":"Marie Bashir Institute for Infectious Diseases and Biosecurity, The University of Sydney, Camperdown, NSW, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Cattaneo","sequence":"additional","affiliation":[{"name":"Unit of Clinical Pharmacology, Fatebenefratelli Sacco University Hospital, Milan, Italy;"},{"name":"Gestione Ambulatoriale Politerapie (GAP) Outpatient Clinic, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah J.E.","family":"Marriott","sequence":"additional","affiliation":[{"name":"St Vincent's Clinical School, University of New South Wales, Kensington, NSW Australia; and"},{"name":"Department of Microbiology and Infectious Diseases, St. Vincent's Hospital, Darlinghurst, NSW, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"suppl 2","key":"R1-20250603","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1093\/mmy\/myy052","article-title":"Broad spectrum triazoles for invasive mould infections in adults: which drug and when?","volume":"57","author":"Jenks","year":"2019","journal-title":"Med Mycol."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1128\/AAC.44.4.1108-1111.2000","article-title":"Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans","volume":"44","author":"Ernst","year":"2000","journal-title":"Antimicrob Agents Chemother."},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1345\/aph.1M237","article-title":"Echinocandins: the newest class of antifungals","volume":"43","author":"Sucher","year":"2009","journal-title":"Ann Pharmacother."},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis."},{"issue":"suppl 7","key":"R5-20250603","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12039","article-title":"ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients","volume":"18","author":"Cornely","year":"2012","journal-title":"Clin Microbiol Infect."},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1128\/JCM.02120-10","article-title":"Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin","volume":"49","author":"Pfaller","year":"2011","journal-title":"J Clin Microbiol."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"R1121","DOI":"10.1016\/j.cub.2008.09.039","article-title":"The evolution of haploidy and diploidy","volume":"18","author":"Otto","year":"2008","journal-title":"Curr Biol."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1093\/cid\/ciu407","article-title":"FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia","volume":"59","author":"Beyda","year":"2014","journal-title":"Clin Infect Dis."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1128\/AAC.01061-07","article-title":"In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model","volume":"52","author":"Andes","year":"2008","journal-title":"Antimicrob Agents Chemother."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1128\/AAC.01337-06","article-title":"Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia","volume":"51","author":"Gumbo","year":"2007","journal-title":"Antimicrob Agents Chemother."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1128\/AAC.00478-08","article-title":"In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model","volume":"52","author":"Andes","year":"2008","journal-title":"Antimicrob Agents Chemother."},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"e02154-17","DOI":"10.1128\/AAC.02154-17","article-title":"Pharmacodynamics of a long-acting echinocandin, CD101, in a neutropenic invasive-candidiasis murine model using an extended-interval dosing design","volume":"62","author":"Lepak","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"e01572-18","DOI":"10.1128\/AAC.01572-18","article-title":"Pharmacodynamic evaluation of rezafungin (CD101) against Candida auris in the neutropenic mouse invasive candidiasis model","volume":"62","author":"Lepak","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/bcp.14457","article-title":"Population pharmacokinetics of anidulafungin in ICU patients assessing inter- and intrasubject variability","volume":"87","author":"Kapralos","year":"2021","journal-title":"Br J Clin Pharmacol."},{"key":"R18-20250603","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00345-20","article-title":"Nonstationary pharmacokinetics of caspofungin in ICU patients","volume":"64","author":"Borsuk-De Moor","year":"2020","journal-title":"Antimicrob Agents Chemother."},{"key":"R19-20250603","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13054-018-2019-8","article-title":"Population pharmacokinetics\/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients","volume":"22","author":"Maseda","year":"2018","journal-title":"Crit Care"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/jac\/dkl015","article-title":"Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis","volume":"57","author":"van Vianen","year":"2006","journal-title":"J Antimicrob Chemother."},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1128\/AAC.49.12.5058-5068.2005","article-title":"Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity","volume":"49","author":"Louie","year":"2005","journal-title":"Antimicrob Agents Chemother."},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1128\/AAC.46.3.739-745.2002","article-title":"Single- and multiple-dose pharmacokinetics of caspofungin in healthy men","volume":"46","author":"Stone","year":"2002","journal-title":"Antimicrob Agents Chemother."},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1128\/AAC.01584-09","article-title":"In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species","volume":"54","author":"Andes","year":"2010","journal-title":"Antimicrob Agents Chemother."},{"key":"R24-20250603","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1128\/AAC.46.6.1857-1869.2002","article-title":"Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits","volume":"46","author":"Petraitis","year":"2002","journal-title":"Antimicrob Agents Chemother."},{"key":"R25-20250603","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1128\/AAC.01480-08","article-title":"Anidulafungin is fungicidal and exerts a variety of postantifungal effects against Candida albicans, C. glabrata, C. parapsilosis, and C. krusei isolates","volume":"53","author":"Nguyen","year":"2009","journal-title":"Antimicrob Agents Chemother."},{"key":"R26-20250603","doi-asserted-by":"crossref","first-page":"e00758-17","DOI":"10.1128\/AAC.00758-17","article-title":"Pharmacological basis of CD101 efficacy: exposure shape matters","volume":"61","author":"Lakota","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"R27-20250603","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.cmi.2020.03.008","article-title":"How to design a study to evaluate therapeutic drug monitoring in infectious diseases?","volume":"26","author":"M\u00e4rtson","year":"2020","journal-title":"Clin Microbiol Infect."},{"key":"R29-20250603","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/jac\/dkq081","article-title":"Echinocandin pharmacodynamics: review and clinical implications","volume":"65","author":"Pound","year":"2010","journal-title":"J Antimicrob Chemother."},{"key":"R30-20250603","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01582-16","article-title":"Low caspofungin exposure in patients in intensive care units","volume":"61","author":"van der Elst","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"R31-20250603","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1080\/1120009X.2020.1737783","article-title":"Caspofungin PK in critically ill patients after the first and fourth doses: suggestions for therapeutic drug monitoring?","volume":"32","author":"Adembri","year":"2020","journal-title":"J Chemother."},{"key":"R32-20250603","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1128\/AAC.01430-10","article-title":"Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia","volume":"55","author":"Andes","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"key":"R33-20250603","doi-asserted-by":"crossref","first-page":"e01398-17","DOI":"10.1128\/AAC.01398-17","article-title":"Pharmacokinetic properties of micafungin in critically ill patients diagnosed with invasive candidiasis","volume":"61","author":"Boonstra","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"R34-20250603","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1128\/AAC.00623-15","article-title":"Altered micafungin pharmacokinetics in intensive care unit patients","volume":"59","author":"Lempers","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"R35-20250603","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1093\/jac\/dkaa265","article-title":"Comparative pharmacokinetics of the three echinocandins in ICU patients","volume":"75","author":"Mainas","year":"2020","journal-title":"J Antimicrob Chemother."},{"key":"R36-20250603","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1177\/0091270005278601","article-title":"Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers","volume":"45","author":"Hebert","year":"2005","journal-title":"J Clin Pharmacol."},{"key":"R37-20250603","doi-asserted-by":"crossref","first-page":"e01894-16","DOI":"10.1128\/AAC.01894-16","article-title":"Pharmacokinetics of anidulafungin in critically ill intensive care unit patients with suspected or proven invasive fungal infections","volume":"61","author":"Br\u00fcggemann","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"R38-20250603","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13054-015-0758-3","article-title":"Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: data from multinational defining antibiotic levels in intensive care unit (DALI) patients Study","volume":"19","author":"Sinnollareddy","year":"2015","journal-title":"Crit Care"},{"key":"R39-20250603","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/0091270006296764","article-title":"Lack of pharmacokinetic interaction between anidulafungin and tacrolimus","volume":"47","author":"Dowell","year":"2007","journal-title":"J Clin Pharmacol."},{"key":"R40-20250603","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ijantimicag.2015.08.009","article-title":"Assessment of echinocandin regimens by pharmacokinetic\/pharmacodynamic analysis against Candida spp. in paediatric patients","volume":"46","author":"Xu","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"R41-20250603","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/jac\/dkaa005","article-title":"Methodological features of clinical pharmacokinetic-pharmacodynamic studies of antibacterials and antifungals: a systematic review","volume":"75","author":"McAleenan","year":"2020","journal-title":"J Antimicrob Chemother."},{"key":"R42-20250603","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0140-6736(03)14472-8","article-title":"Echinocandin antifungal drugs","volume":"362","author":"Denning","year":"2003","journal-title":"Lancet"},{"key":"R43-20250603","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1128\/AAC.05134-11","article-title":"Phase II dose escalation study of caspofungin for invasive Aspergillosis","volume":"55","author":"Cornely","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"key":"R44-20250603","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/sj.bmt.1705398","article-title":"A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation","volume":"38","author":"Sirohi","year":"2006","journal-title":"Bone Marrow Transpl."},{"key":"R45-20250603","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s10096-019-03617-9","article-title":"Evaluation of anidulafungin in the treatment of intra-abdominal candidiasis: a pooled analysis of patient-level data from 5 prospective studies","volume":"38","author":"Sganga","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"R46-20250603","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/INF.0000000000002237","article-title":"A prospective, open-label study to assess the safety, tolerability and efficacy of anidulafungin in the treatment of invasive candidiasis in children 2 to","volume":"38","author":"Roilides","year":"2019","journal-title":"Pediatr Infect Dis J."},{"key":"R47-20250603","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1186\/s12879-018-3333-0","article-title":"Retrospective cohort study comparing the risk of severe hepatotoxicity in hospitalized patients treated with echinocandins for invasive candidiasis in the presence of confounding by indication","volume":"18","author":"Vekeman","year":"2018","journal-title":"BMC Infect Dis."},{"key":"R48-20250603","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1093\/jac\/dkv235","article-title":"Switching to anidulafungin from caspofungin in cancer patients in the setting of liver dysfunction is associated with improvement of liver function tests","volume":"70","author":"Jung","year":"2015","journal-title":"J Antimicrob Chemother."},{"key":"R49-20250603","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1086\/598933","article-title":"A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis","volume":"48","author":"Betts","year":"2009","journal-title":"Clin Infect Dis."},{"key":"R50-20250603","doi-asserted-by":"crossref","first-page":"e291-8","DOI":"10.1097\/INF.0000000000000434","article-title":"Micafungin in premature and non-premature infants: a systematic review of 9 clinical trials","volume":"33","author":"Manzoni","year":"2014","journal-title":"Pediatr Infect Dis J."},{"key":"R51-20250603","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/sj.bmt.1705563","article-title":"Increased dose of echinocandins for invasive fungal infections: bonanza for the patient or the pharmaceutical industry?","volume":"39","author":"Chandrasekar","year":"2007","journal-title":"Bone Marrow Transpl."},{"key":"R52-20250603","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1074\/jbc.271.24.14604","article-title":"In vitro activity of 1,3-beta-D-glucan synthase requires the GTP-binding protein Rho1","volume":"271","author":"Mazur","year":"1996","journal-title":"J Biol Chem."},{"key":"R53-20250603","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1086\/344058","article-title":"Antifungal resistance in pathogenic fungi","volume":"35","author":"Perea","year":"2002","journal-title":"Clin Infect Dis."},{"key":"R54-20250603","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1128\/AAC.41.11.2471","article-title":"Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors","volume":"41","author":"Douglas","year":"1997","journal-title":"Antimicrob Agents Chemother."},{"key":"R55-20250603","doi-asserted-by":"crossref","first-page":"e02644-16","DOI":"10.1128\/AAC.02644-16","article-title":"Molecular confirmation of the relationship between Candida guilliermondii Fks1p naturally occurring amino acid substitutions and its intrinsic reduced echinocandin susceptibility","volume":"61","author":"Dudiuk","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"R56-20250603","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1128\/AAC.00262-08","article-title":"A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility","volume":"52","author":"Garcia-Effron","year":"2008","journal-title":"Antimicrob Agents Chemother."},{"key":"R57-20250603","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.drup.2007.04.002","article-title":"Resistance to echinocandin-class antifungal drugs","volume":"10","author":"Perlin","year":"2007","journal-title":"Drug Resist Updat"},{"key":"R58-20250603","doi-asserted-by":"crossref","first-page":"3690","DOI":"10.1128\/AAC.00443-09","article-title":"Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint","volume":"53","author":"Garcia-Effron","year":"2009","journal-title":"Antimicrob Agents Chemother."},{"key":"R59-20250603","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1345\/aph.1R020","article-title":"Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches","volume":"46","author":"Beyda","year":"2012","journal-title":"Ann Pharmacother."},{"key":"R60-20250603","doi-asserted-by":"crossref","first-page":"e1000040","DOI":"10.1371\/journal.ppat.1000040","article-title":"Stimulation of chitin synthesis rescues Candida albicans from echinocandins","volume":"4","author":"Walker","year":"2008","journal-title":"Plos Pathog."},{"key":"R61-20250603","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1128\/AAC.00095-07","article-title":"Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences","volume":"51","author":"Chamilos","year":"2007","journal-title":"Antimicrob Agents Chemother."},{"key":"R62-20250603","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1128\/AAC.00999-10","article-title":"Paradoxical effect of caspofungin against Candida bloodstream isolates is mediated by multiple pathways but eliminated in human serum","volume":"55","author":"Shields","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"key":"R63-20250603","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/jof4010005","article-title":"Recent insights into the paradoxical effect of echinocandins","volume":"4","author":"Wagener","year":"2017","journal-title":"J Fungi (Basel)"},{"key":"R64-20250603","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1128\/AAC.06369-11","article-title":"Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations","volume":"56","author":"Arendrup","year":"2012","journal-title":"Antimicrob Agents Chemother."},{"key":"R65-20250603","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1128\/AAC.00538-06","article-title":"In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility","volume":"50","author":"Cota","year":"2006","journal-title":"Antimicrob Agents Chemother."},{"key":"R66-20250603","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1128\/AAC.01750-10","article-title":"Caspofungin dose escalation for invasive candidiasis due to resistant Candida albicans","volume":"55","author":"Wiederhold","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"key":"R67-20250603","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1128\/AAC.00123-14","article-title":"Positions and numbers of FKS mutations in Candida albicans selectively influence in vitro and in vivo susceptibilities to echinocandin treatment","volume":"58","author":"Lackner","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"R68-20250603","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/cid\/cit136","article-title":"Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations","volume":"56","author":"Alexander","year":"2013","journal-title":"Clin Infect Dis."},{"key":"R69-20250603","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s15010-020-01475-8","article-title":"Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland","volume":"48","author":"Coste","year":"2020","journal-title":"Infection"},{"key":"R70-20250603","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1128\/AAC.02139-12","article-title":"Pharmacokinetics of anidulafungin in critically ill patients with candidemia\/invasive candidiasis","volume":"57","author":"Liu","year":"2013","journal-title":"Antimicrob Agents Chemother."},{"key":"R71-20250603","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/0091270007303764","article-title":"Single- and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations","volume":"47","author":"Mistry","year":"2007","journal-title":"J Clin Pharmacol."},{"key":"R72-20250603","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00228-011-1066-8","article-title":"Pharmacokinetics of caspofungin in a critically ill patient with liver cirrhosis","volume":"67","author":"Spriet","year":"2011","journal-title":"Eur J Clin Pharmacol."},{"key":"R73-20250603","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s40262-015-0347-2","article-title":"Dose reduction of caspofungin in intensive care unit patients with child pugh B will result in suboptimal exposure","volume":"55","author":"Martial","year":"2016","journal-title":"Clin Pharmacokinet."},{"key":"R74-20250603","doi-asserted-by":"crossref","first-page":"e02466-18","DOI":"10.1128\/AAC.02466-18","article-title":"Pharmacokinetics of caspofungin in critically ill patients in relation to liver dysfunction: differential impact of plasma albumin and bilirubin levels","volume":"63","author":"Kurland","year":"2019","journal-title":"Antimicrob Agents Chemother."},{"key":"R75-20250603","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1093\/jac\/dky189","article-title":"Caspofungin dosage adjustments are not required for patients with Child-Pugh B or C cirrhosis","volume":"73","author":"Gustot","year":"2018","journal-title":"J Antimicrob Chemother."},{"key":"R76-20250603","doi-asserted-by":"crossref","first-page":"17741","DOI":"10.1038\/s41598-019-53093-6","article-title":"Pharmacokinetics of micafungin in critically ill patients","volume":"9","author":"Gastine","year":"2019","journal-title":"Sci Rep."},{"key":"R77-20250603","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1248\/bpb.32.750","article-title":"The impact of total bilirubin on plasma micafungin levels in living-donor liver transplantation recipients with severe liver dysfunction","volume":"32","author":"Muraki","year":"2009","journal-title":"Biol Pharm Bull."},{"key":"R78-20250603","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1128\/AAC.00335-13","article-title":"Pharmacokinetics of caspofungin in critically ill patients on continuous renal replacement therapy","volume":"57","author":"Weiler","year":"2013","journal-title":"Antimicrob Agents Chemother."},{"key":"R79-20250603","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s40262-016-0495-z","article-title":"Caspofungin population pharmacokinetics in critically ill patients undergoing continuous veno-venous haemofiltration or haemodiafiltration","volume":"56","author":"Roger","year":"2017","journal-title":"Clin Pharmacokinet."},{"key":"R80-20250603","doi-asserted-by":"crossref","first-page":"e02425-16","DOI":"10.1128\/AAC.02425-16","article-title":"Micafungin plasma levels are not affected by continuous renal replacement therapy: experience in critically ill patients","volume":"61","author":"Vossen","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"R81-20250603","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/FTD.0000000000000595","article-title":"Pharmacokinetics of micafungin in critically ill patients receiving continuous venovenous hemodialysis with high cutoff membranes","volume":"41","author":"Tenorio-Ca\u00f1am\u00e1s","year":"2019","journal-title":"Ther Drug Monit."},{"key":"R82-20250603","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1179\/1973947813Y.0000000089","article-title":"Pharmacokinetics of anidulafungin in two critically ill patients with septic shock undergoing CVVH","volume":"25","author":"De Rosa","year":"2013","journal-title":"J Chemother."},{"key":"R83-20250603","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1093\/jac\/dkq545","article-title":"Multiple-dose pharmacokinetics of anidulafungin during continuous venovenous haemofiltration","volume":"66","author":"Leitner","year":"2011","journal-title":"J Antimicrob Chemother."},{"key":"R84-20250603","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000489212","article-title":"Ex vivo rezafungin adsorption and clearance during continuous renal replacement therapy","volume":"46","author":"Jang","year":"2018","journal-title":"Blood Purif."},{"key":"R85-20250603","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1186\/s13054-015-1151-y","article-title":"Can physicochemical properties of antimicrobials be used to predict their pharmacokinetics during extracorporeal membrane oxygenation? Illustrative data from ovine models","volume":"19","author":"Shekar","year":"2015","journal-title":"Crit Care"},{"key":"R86-20250603","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/jac\/dkp026","article-title":"Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation","volume":"63","author":"Spriet","year":"2009","journal-title":"J Antimicrob Chemother."},{"key":"R87-20250603","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.mmcr.2012.12.006","article-title":"Insufficient serum caspofungin levels in a paediatric patient on ECMO","volume":"2","author":"Koch","year":"2012","journal-title":"Med Mycol Case Rep."},{"key":"R88-20250603","doi-asserted-by":"crossref","first-page":"277","DOI":"10.5935\/0103-507X.20200044","article-title":"Pharmacokinetics of micafungin in patients treated with extracorporeal membrane oxygenation: an observational prospective study","volume":"32","author":"L\u00f3pez-S\u00e1nchez","year":"2020","journal-title":"Rev Bras Ter Intensiva"},{"key":"R89-20250603","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1051\/ject\/201749150","article-title":"Antifungal extraction by the extracorporeal membrane oxygenation circuit","volume":"49","author":"Watt","year":"2017","journal-title":"J Extra Corpor Technol."},{"key":"R90-20250603","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/s13054-016-1501-4","article-title":"Pharmacokinetics of anidulafungin during venovenous extracorporeal membrane oxygenation","volume":"20","author":"Aguilar","year":"2016","journal-title":"Crit Care"},{"key":"R91-20250603","doi-asserted-by":"crossref","first-page":"e00905-20","DOI":"10.1128\/AAC.00905-20","article-title":"Caspofungin weight-based dosing supported by a population pharmacokinetic model in critically ill patients","volume":"64","author":"M\u00e4rtson","year":"2020","journal-title":"Antimicrob Agents Chemother."},{"key":"R92-20250603","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/jac\/dky554","article-title":"Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adults","volume":"74","author":"Wasmann","year":"2019","journal-title":"J Antimicrob Chemother."},{"key":"R93-20250603","doi-asserted-by":"crossref","first-page":"e00063-18","DOI":"10.1128\/AAC.00063-18","article-title":"Pharmacokinetics of anidulafungin in obese and normal-weight Adults","volume":"62","author":"Wasmann","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"R94-20250603","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s40262-016-0401-8","article-title":"Does weight impact anidulafungin pharmacokinetics?","volume":"55","author":"Lempers","year":"2016","journal-title":"Clin Pharmacokinet."},{"key":"R95-20250603","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1128\/AAC.48.11.4306-4314.2004","article-title":"Potential for interactions between caspofungin and nelfinavir or rifampin","volume":"48","author":"Stone","year":"2004","journal-title":"Antimicrob Agents Chemother."},{"key":"R96-20250603","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s40262-017-0578-5","article-title":"Clinical pharmacokinetics and pharmacodynamics of micafungin","volume":"57","author":"Wasmann","year":"2018","journal-title":"Clin Pharmacokinet."},{"key":"R97-20250603","doi-asserted-by":"crossref","first-page":"237","DOI":"10.5414\/CP202015","article-title":"Pharmacokinetic profile of micafungin when co-administered with amphotericin B in healthy male subjects","volume":"52","author":"Undre","year":"2014","journal-title":"Int J Clin Pharmacol Ther."},{"key":"R98-20250603","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1177\/0091270005281234","article-title":"Safety and pharmacokinetics of coadministered voriconazole and anidulafungin","volume":"45","author":"Dowell","year":"2005","journal-title":"J Clin Pharmacol."},{"key":"R99-20250603","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1177\/0091270004265644","article-title":"Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal","volume":"44","author":"Dowell","year":"2004","journal-title":"J Clin Pharmacol."},{"key":"R100-20250603","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1128\/AAC.02931-15","article-title":"Inhibitory potential of antifungal drugs on ATP-binding cassette transporters P-glycoprotein, MRP1 to MRP5, BCRP, and BSEP","volume":"60","author":"Lempers","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"key":"R101-20250603","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.4155\/bio-2019-0045","article-title":"Chromatographic methods for echinocandin antifungal drugs determination in bioanalysis","volume":"11","author":"Uribe","year":"2019","journal-title":"Bioanalysis"},{"key":"R102-20250603","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1128\/AAC.00404-10","article-title":"Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin","volume":"54","author":"Decosterd","year":"2010","journal-title":"Antimicrob Agents Chemother."},{"key":"R103-20250603","doi-asserted-by":"crossref","first-page":"121937","DOI":"10.1016\/j.jchromb.2019.121937","article-title":"Quantification of anidulafungin and micafungin in human body fluids by high performance-liquid chromatography with UV-detection","volume":"1139","author":"Welte","year":"2020","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R104-20250603","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.jchromb.2011.05.033","article-title":"Determination of micafungin and anidulafungin in human plasma: UV- or mass spectrometric quantification?","volume":"879","author":"Martens-Lobenhoffer","year":"2011","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R105-20250603","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/FTD.0b013e31829591a7","article-title":"Simultaneous quantification of anidulafungin and caspofungin in plasma by an accurate and simple liquid chromatography tandem mass-spectrometric method","volume":"35","author":"van Wanrooy","year":"2013","journal-title":"Ther Drug Monit."},{"key":"R106-20250603","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0003-2670(97)00263-8","article-title":"Determination of a cyclic hexapeptide (L-743 872), a novel pneumocandin antifungal agent in human plasma and urine by high-performance liquid chromatography with fluorescence detection","volume":"352","author":"Schwartz","year":"1997","journal-title":"Analytica Chim Acta"},{"key":"R107-20250603","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1128\/AAC.01276-09","article-title":"Quantitation of azoles and echinocandins in compartments of peripheral blood by liquid chromatography-tandem mass spectrometry","volume":"54","author":"Farowski","year":"2010","journal-title":"Antimicrob Agents Chemother."},{"key":"R108-20250603","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s00216-013-7590-x","article-title":"Quantification of micafungin in human plasma by liquid chromatography-tandem mass spectrometry","volume":"406","author":"Cangemi","year":"2014","journal-title":"Anal Bioanal Chem."},{"key":"R109-20250603","doi-asserted-by":"crossref","first-page":"877","DOI":"10.4155\/bio-2017-0275","article-title":"Simple and robust LC-MS\/MS analysis method for therapeutic drug monitoring of micafungin","volume":"10","author":"Boonstra","year":"2018","journal-title":"Bioanalysis"},{"key":"R110-20250603","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0378-4347(98)00447-2","article-title":"Determination of a cyclic hexapeptide, a novel antifungal agent, in human plasma by high-performance liquid chromatography with ion spray and turbo ion spray tandem mass spectrometric detection","volume":"721","author":"Chavez-Eng","year":"1999","journal-title":"J Chromatogr B Biomed Sci Appl."},{"key":"R111-20250603","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1007\/s00216-012-6272-4","article-title":"Anidulafungin\u2014challenges in development and validation of an LC-MS\/MS bioanalytical method validated for regulated clinical studies","volume":"404","author":"Alebic-Kolbah","year":"2012","journal-title":"Anal Bioanal Chem."},{"key":"R112-20250603","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02603-17","article-title":"Population pharmacokinetic analyses for rezafungin (CD101) efficacy using phase 1 data","volume":"62","author":"Lakota","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"R113-20250603","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/cpdd.757","article-title":"Lack of effect of rezafungin on QT\/QTc interval in healthy subjects","volume":"9","author":"Flanagan","year":"2020","journal-title":"Clin Pharmacol Drug Dev."},{"key":"R114-20250603","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1515\/CCLM.2002.172","article-title":"Clinical utility of free drug monitoring","volume":"40","author":"Dasgupta","year":"2002","journal-title":"Clin Chem Lab Med."},{"key":"R115-20250603","doi-asserted-by":"crossref","first-page":"767","DOI":"10.4155\/bio-2017-0053","article-title":"Measuring and using free drug concentrations: has there been \u2018real\u2019 progress?","volume":"9","author":"Musteata","year":"2017","journal-title":"Bioanalysis"},{"key":"R116-20250603","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1128\/AAC.01647-09","article-title":"Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients","volume":"54","author":"Walsh","year":"2010","journal-title":"Antimicrob Agents Chemother."},{"key":"R117-20250603","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1128\/AAC.01607-13","article-title":"Low but sufficient anidulafungin exposure in critically ill patients","volume":"58","author":"van Wanrooy","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"R118-20250603","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1128\/AAC.03375-14","article-title":"Limited-sampling strategies for anidulafungin in critically ill patients","volume":"59","author":"van Wanrooy","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"key":"R119-20250603","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1128\/AAC.01912-12","article-title":"Population pharmacokinetics of escalating doses of caspofungin in a phase II study of patients with invasive aspergillosis","volume":"57","author":"W\u00fcrthwein","year":"2013","journal-title":"Antimicrob Agents Chemother."},{"key":"R120-20250603","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1128\/AAC.01473-12","article-title":"Population pharmacokinetic-pharmacodynamic analysis of anidulafungin in adult patients with fungal infections","volume":"57","author":"Liu","year":"2013","journal-title":"Antimicrob Agents Chemother."},{"key":"R121-20250603","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/INF.0b013e31824ab9b0","article-title":"Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia","volume":"31","author":"Undre","year":"2012","journal-title":"Pediatr Infect Dis J."},{"key":"R122-20250603","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1080\/17425255.2019.1671971","article-title":"Therapeutic drug monitoring of systemic antifungal agents: a pragmatic approach for adult and pediatric patients","volume":"15","author":"John","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R123-20250603","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13054-015-0891-z","article-title":"Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: results from an ex vivo study","volume":"19","author":"Shekar","year":"2015","journal-title":"Crit Care"},{"key":"R124-20250603","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1124\/dmd.104.003244","article-title":"Hepatic uptake of the novel antifungal agent caspofungin","volume":"33","author":"Sandhu","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"R125-20250603","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s10096-004-1228-z","article-title":"Pharmacokinetics\/pharmacodynamics of echinocandins","volume":"23","author":"Theuretzbacher","year":"2004","journal-title":"Eur J Clin Microbiol Infect Dis."},{"key":"R126-20250603","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/0091270004270146","article-title":"Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine","volume":"45","author":"Dowell","year":"2005","journal-title":"J Clin Pharmacol."},{"key":"R127-20250603","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3390\/jof6040192","article-title":"Review of the novel echinocandin antifungal rezafungin: animal studies and clinical data","volume":"6","author":"Zhao","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"R128-20250603","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1177\/0091270009360982","article-title":"Lack of pharmacokinetic drug interaction between oral posaconazole and caspofungin or micafungin","volume":"51","author":"Krishna","year":"2011","journal-title":"J Clin Pharmacol."},{"key":"R129-20250603","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1007\/s11095-014-1595-9","article-title":"Physiology-based pharmacokinetics of caspofungin for adults and paediatrics","volume":"32","author":"Stader","year":"2015","journal-title":"Pharm Res."},{"key":"R130-20250603","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1128\/AAC.00265-11","article-title":"Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients","volume":"56","author":"W\u00fcrthwein","year":"2012","journal-title":"Antimicrob Agents Chemother."},{"key":"R131-20250603","doi-asserted-by":"crossref","first-page":"831","DOI":"10.5414\/CP201738","article-title":"Drug interactions between micafungin at high doses and cyclosporine A in febrile neutropenia patients after allogeneic hematopoietic stem cell transplantation","volume":"50","author":"Inoue","year":"2012","journal-title":"Int J Clin Pharmacol Ther."},{"key":"R132-20250603","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1177\/0091270005279274","article-title":"Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers","volume":"45","author":"Hebert","year":"2005","journal-title":"J Clin Pharmacol."},{"key":"R133-20250603","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1128\/AAC.00673-06","article-title":"Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults","volume":"51","author":"Keirns","year":"2007","journal-title":"Antimicrob Agents Chemother."},{"key":"R134-20250603","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1002\/rcm.1691","article-title":"An advanced double column-switching technique (LC-LC) for liquid chromatography\/electrospray ionisation tandem mass spectrometry for fully automated analysis of caspofungin","volume":"18","author":"Egle","year":"2004","journal-title":"Rapid Commun MA Spectrom."},{"key":"R135-20250603","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1248\/bpb.28.477","article-title":"Analysis of the blood level of micafungin involving patients with hematological diseases: new findings regarding combination therapy with tacrolimus","volume":"28","author":"Shimoeda","year":"2005","journal-title":"Biol Pharm Bull."},{"key":"R136-20250603","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/jms.1171","article-title":"Liquid chromatography-mass spectrometry method for quantification of caspofungin in clinical plasma samples","volume":"42","author":"Rochat","year":"2007","journal-title":"J MA Spectrom."},{"key":"R137-20250603","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/chromsci\/49.5.397","article-title":"Development of an HPLC method for the determination of anidulafungin in human plasma and saline","volume":"49","author":"Sutherland","year":"2011","journal-title":"J Chromatogr Sci."},{"key":"R138-20250603","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jchromb.2011.03.008","article-title":"Direct-injection HPLC method of measuring micafungin in human plasma using a novel hydrophobic\/hydrophilic hybrid ODS column","volume":"879","author":"Uranishi","year":"2011","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R139-20250603","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/bmc.2822","article-title":"Simple column-switching HPLC method for determining levels of the antifungal agent micafungin in human plasma and application to patient samples","volume":"27","author":"Nakagawa","year":"2013","journal-title":"Biomed Chromatogr."},{"key":"R140-20250603","first-page":"521","article-title":"An on-line solid phase extraction procedure for the routine quantification of caspofungin by liquid chromatography-tandem mass spectrometry","volume":"50","author":"Kirchhoff","year":"2011","journal-title":"Clin Chem Lab Med."},{"key":"R141-20250603","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1093\/jac\/dkt542","article-title":"Anidulafungin dosing in critically ill patients with continuous venovenous haemodiafiltration","volume":"69","author":"Aguilar","year":"2014","journal-title":"J Antimicrob Chemother."},{"key":"R142-20250603","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jchromb.2017.01.036","article-title":"An ultra performance liquid chromatography-tandem mass spectrometry method for the therapeutic drug monitoring of isavuconazole and seven other antifungal compounds in plasma samples","volume":"1046","author":"Toussaint","year":"2017","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"R143-20250603","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/rcm.8100","article-title":"Development and validation of a liquid chromatography\/tandem mass spectrometry method for determination of caspofungin in dried blood spots","volume":"32","author":"Cheng","year":"2018","journal-title":"Rapid Commun MA Spectrom."},{"key":"R144-20250603","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jpba.2018.05.015","article-title":"Liquid chromatography-tandem mass spectrometry for the quantification of moxifloxacin, ciprofloxacin, daptomycin, caspofungin, and isavuconazole in human plasma","volume":"157","author":"H\u00f6sl","year":"2018","journal-title":"J Pharm Biomed Anal."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000931","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:30:31Z","timestamp":1748971831000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":140,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000931","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"2021-06-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}